Literature DB >> 11018791

Comparison of the effects of sibutramine and other weight-modifying drugs on extracellular dopamine in the nucleus accumbens of freely moving rats.

H L Rowley1, S A Butler, M R Prow, S G Dykes, S Aspley, I C Kilpatrick, D J Heal.   

Abstract

The acute effects of systemic administration of the anti-obesity agent sibutramine on extracellular dopamine (DA) in the nucleus accumbens of freely moving rats were studied using in vivo microdialysis and compared with the actions of phentermine and d-amphetamine at doses 1x and 3x their respective 2 h ED(50) values to reduce food intake in rats. At the lower dose, sibutramine did not elevate extracellular DA concentrations; however, at the higher dose (6.0 mg kg(-1), i.p.) it caused a modest and prolonged increase in extraneuronal DA. A maximal rise was observed at 60 min post-sibutramine treatment (+231% compared to controls) with DA levels remaining elevated for up to 160 min post treatment. In contrast, phentermine and d-amphetamine significantly enhanced DA efflux at both the lower and higher doses. These elevations of DA levels were significantly greater than that seen with the corresponding dose of sibutramine over 0-80 min post treatment. Maximal rises in DA levels resulting from the higher dose of each drug were +733% (phentermine, 3.9 mg kg(-1), i.p.) and +603% (d-amphetamine, 1.5 mg kg(-1), i.p.) compared to controls 40 min post treatment. The highest doses of phentermine and d-amphetamine increased rat locomotor activity up to 100 min and 160 min post treatment, respectively, whereas the equivalent sibutramine dose had no effect. These findings therefore suggest that dopaminergic reward mechanisms are not involved in the reduction of food intake by sibutramine. Furthermore, they are consistent with the view that sibutramine lacks abuse potential. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11018791     DOI: 10.1002/1098-2396(200011)38:2<167::AID-SYN8>3.0.CO;2-W

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  11 in total

Review 1.  Antiobesity drugs: current and future issues.

Authors:  M Ammar Hatahet; Nikhil V Dhurandhar
Journal:  Curr Diab Rep       Date:  2002-10       Impact factor: 4.810

Review 2.  Central nervous system biogenic amine targets for control of appetite and energy expenditure.

Authors:  David L Nelson; Donald R Gehlert
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

3.  MSI-1436 reduces acute food intake without affecting dopamine transporter activity.

Authors:  Mitchell F Roitman; Seth Wescott; Jackson J Cone; Michael P McLane; Henry R Wolfe
Journal:  Pharmacol Biochem Behav       Date:  2010-05-15       Impact factor: 3.533

Review 4.  What pharmacological interventions are effective in binge-eating disorder? Insights from a critical evaluation of the evidence from clinical trials.

Authors:  David J Heal; Jane Gosden
Journal:  Int J Obes (Lond)       Date:  2022-01-07       Impact factor: 5.551

5.  The anorexic agents, sibutramine and fenfluramine, depress GABA(B)-induced inhibitory postsynaptic potentials in rat mesencephalic dopaminergic cells.

Authors:  Ada Ledonne; Luca Sebastianelli; Mauro Federici; Giorgio Bernardi; Nicola Biagio Mercuri
Journal:  Br J Pharmacol       Date:  2009-03       Impact factor: 8.739

Review 6.  The use of serotonergic drugs to treat obesity--is there any hope?

Authors:  Nicholas T Bello; Nu-Chu Liang
Journal:  Drug Des Devel Ther       Date:  2011-02-10       Impact factor: 4.162

Review 7.  Treatment of Acquired Hypothalamic Obesity: Now and the Future.

Authors:  Paul Dimitri
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-06       Impact factor: 6.055

8.  5-alpha-dihydrotestosterone elevations associated with phentermine use.

Authors:  Scott M Pearson; Jennifer M Trujillo; Michael T McDermott
Journal:  Ther Adv Endocrinol Metab       Date:  2018-05-20       Impact factor: 3.565

Review 9.  Amphetamine, past and present--a pharmacological and clinical perspective.

Authors:  David J Heal; Sharon L Smith; Jane Gosden; David J Nutt
Journal:  J Psychopharmacol       Date:  2013-03-28       Impact factor: 4.153

10.  Stimulants for the Control of Hedonic Appetite.

Authors:  Alison S Poulton; Emily J Hibbert; Bernard L Champion; Ralph K H Nanan
Journal:  Front Pharmacol       Date:  2016-04-25       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.